Mogilarta (Hydrochlorothiazide, Telmisartan)

Mogilarta combines an angiotensin II receptor blocker with a thiazide diuretic to manage elevated blood pressure across the hypertension spectrum.

• Essential hypertension: lowers systolic and diastolic pressure to reduce cardiovascular risk.
• Secondary hypertension: assists in blood‑pressure control when underlying causes are being treated.
• Isolated systolic hypertension: improves pulse pressure in older adults.

• Telmisartan selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits NaCl reabsorption in the distal convoluted tubule, increasing urinary sodium and water excretion. The combined actions reduce peripheral vascular resistance and plasma volume, resulting in sustained blood‑pressure reduction.

Mogilarta may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue or weakness
• Increased urinary frequency
• Electrolyte disturbances (e.g., low potassium)
• Mild gastrointestinal upset

Serious or Rare Side Effects

• Severe dehydration or electrolyte imbalance
• Acute kidney injury or worsening renal function
• Hyperkalemia, especially with potassium‑sparing agents
• Angioedema or severe allergic reaction
• Significant hypotension leading to syncope

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Renal function: assess baseline creatinine and eGFR, then monitor periodically.
• Electrolytes: check serum potassium and sodium, especially when combined with other diuretics.
• Elderly patients: start at lower dose and monitor for orthostatic hypotension.
• Hepatic impairment: use with caution; dose adjustment may be required.
• Concomitant NSAIDs: avoid or monitor renal function closely.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mogilarta can alter the effects of several other medicines; awareness of interaction severity helps guide safe use.

Major Interactions (Avoid)

• Aliskiren in diabetic patients: risk of renal dysfunction and hyperkalemia.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.
• ACE inhibitors or other ARBs: additive effect on potassium and renal function.
• Lithium: increased lithium levels and toxicity.
• Cyclosporine: heightened risk of nephrotoxicity.

Moderate Interactions (Monitor Closely)

• NSAIDs: may blunt antihypertensive response and affect renal function.
• CYP2C9 inhibitors (e.g., fluconazole): can raise telmisartan concentrations.
• Antacids containing aluminum or magnesium: may reduce hydrochlorothiazide absorption.